Scientists have identified a shared regulatory vulnerability in hundreds of cancer mutations, a discovery that could lead to new therapies targeting common control points rather than individual genetic errors. The new research, published in Nature, introduces a platform called PerturbFate, which systematically tracks how disease-related genetic changes alter cells and where these changes converge.
The platform observed gene regulation in single cells over time, uncovering shared regulatory hubs that many different mutations depend on. Using melanoma drug resistance as a test case, researchers demonstrated that targeting these common control points could overcome resistance across multiple genetic causes. The study addresses a broader question: how to design a single therapy for diseases associated with hundreds of genes.
Targeting Shared Signaling Pathways
Advances in genetic sequencing have identified numerous disease-linked mutations. This progress, however, created a challenge. Genes involved in disease often perform diverse functions within cells, controlling gene activity and managing signaling pathways. That complexity has made designing treatments that address many mutations simultaneously difficult.
Junyue Cao, head of the Laboratory of Single-Cell Genomics and Population Dynamics, hypothesized that seemingly unrelated mutations might not act independently. He suggested they could funnel into shared downstream programs determining cell behavior. If correct, scientists could focus on common regulatory nodes, eliminating the need to target each mutation separately. Cao said his team aimed to develop technology to identify these shared regulatory nodes as targets.
PerturbFate's Detailed Cellular View
Graduate student Zihan Xu developed PerturbFate to overcome limitations of existing technologies, which often captured only partial cellular activity or missed dynamic changes in gene activity. The platform enables researchers to observe how different genetic disruptions alter cells in real time by simultaneously tracking DNA accessibility and RNA production within the same single cell. This method reveals gene networks controlling cell behavior and identifies instances where distinct mutations produce identical downstream effects.
To validate PerturbFate, researchers focused on melanoma, where various mutations can lead to treatment resistance.
The team disabled 143 genes previously linked to resistance to the melanoma drug Vemurafenib in melanoma cells. PerturbFate then monitored how each disruption changed cellular behavior over time. Labeling newly produced RNA allowed researchers to differentiate fresh gene activity from older molecular signals. Single-cell profiling also tracked active genes, accessible DNA regions, and their evolution. This detailed approach gave scientists a cell-by-cell view of how different mutations influence gene regulation and where pathways converge. After analyzing over 300,000 cells, the team found many mutations consistently pushed melanoma cells into the same drug-resistant state. Targeting the shared regulatory control points driving that state significantly reduced drug resistance.
COMMENTS